Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

A new study has pitted Wegovy and Zepbound head-to-head in their ability to treat obesity. Published in The New England Journal of Medicine on May 11, the study attempted to analyze the comparative ...

A new study published in the New England ... decreases food intake, so you lose weight,” Azar said. Trizepatide (Zepbound), on the other hand, mimics two different hormones — GLP-1 and ...

Study participants treated with Zepbound lost 20% of their body weight ... approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight ...

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when ...

Zepbound targets two hormones (GLP-1 and GIP), while Wegovy targets only GLP-1, AP reported. "Two drugs together can produce better weight loss," said lead study author Dr. Louis Aronne of Weill ...

Eli Lilly highlighted its drug's effectiveness in helping people lose weight. Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose ...

Two clinical studies, SURMOUNT-1 and SURMOUNT-2, were done to see the benefits and risks of Zepbound for weight loss in adult people with excess weight. The first study, SURMOUNT-1, was done in ...

Folks who take the blockbuster weight-loss med tirzepatide (Zepbound) may regain much of the weight they lost soon after discontinuing it, new research shows. A trial funded by Eli Lilly ...